Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-27), Japan Lifeline Co's 1-Year Sharpe Ratio is 0.02.
Japan Lifeline Co (FRA:L8B) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Japan Lifeline Co 1-Year Sharpe Ratio Related Terms
FRA:L8B vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison
For the Medical Devices subindustry, Japan Lifeline Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Lifeline Co 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Japan Lifeline Co's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Japan Lifeline Co's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Japan Lifeline Co (FRA:L8B) has a 1-Year Sharpe Ratio of 0.02 as of Aug. 27, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Japan Lifeline Co and its competitors.
Is Japan Lifeline Co's 1-Year Sharpe Ratio too high?
Japan Lifeline Co's current 1-Year Sharpe Ratio is 0.02. Overall, Japan Lifeline Co has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Japan Lifeline Co's 1-Year Sharpe Ratio compare to ABT and SYK?
Japan Lifeline Co's 1-Year Sharpe Ratio of 0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Japan Lifeline Co and its competitors. Japan Lifeline Co's current 1-Year Sharpe Ratio is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Lifeline Co stock overvalued right now?
Japan Lifeline Co (FRA:L8B) has a current 1-Year Sharpe Ratio of 0.02. The stock's GF Value™ is €8.16, compared to a current price of €8.30 — trading 1.7% above its estimated fair value. The current 1-Year Sharpe Ratio is 0.02. Japan Lifeline Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Japan Lifeline Co (FRA:L8B), the current 1-Year Sharpe Ratio is 0.02 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Lifeline Co (FRA:L8B) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Lifeline Co stock appears to be overvalued.
The current stock price of €8.30 is trading 1.7% above its estimated GF Value™ of €8.16.
Key valuation signals for FRA:L8B:
1-Year Sharpe Ratio: 0.02
GF Value™: €8.16 vs. price of €8.30 (1.7% above fair value)
No single metric tells the full story. See the FRA:L8B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
93GF Score
Get the complete analysis for FRA:L8B
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L8B has been successfully added to your 
